170 related articles for article (PubMed ID: 34387808)
21. A multiple-center phase II study of weekly docetaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer.
Chen JS; Chen YY; Huang JS; Yeh KY; Chen PT; Shen WC; Hsu HC; Lin YC; Wang HM
Gastric Cancer; 2012 Jan; 15(1):49-55. PubMed ID: 21655995
[TBL] [Abstract][Full Text] [Related]
22. Comparison of Long-Term Efficacy in S-1 and Capecitabine With Oxaliplatin as Adjuvant Chemotherapy for Patients With Gastric Cancer After Curative Surgery: A Retrospective, Single-Center Observational Study.
Oh SE; An JY; Choi MG; Lee JH; Sohn TS; Bae JM
Technol Cancer Res Treat; 2021; 20():15330338211039679. PubMed ID: 34605706
[No Abstract] [Full Text] [Related]
23. Adjuvant treatment combining cellular immunotherapy with chemotherapy improves the clinical outcome of patients with stage II/III gastric cancer.
Wang Y; Wang C; Xiao H; Niu C; Wu H; Jin H; Yao C; He H; Tian H; Han F; Li D; Han W; Xu J; Chen J; Cui J; Li W
Cancer Med; 2017 Jan; 6(1):45-53. PubMed ID: 27790867
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of capecitabine and oxaliplatin versus S-1 as adjuvant chemotherapy in gastric cancer after D2 lymph node dissection according to lymph node ratio and N stage.
Shin K; Park SJ; Lee J; Park CH; Song KY; Lee HH; Seo HS; Jung YJ; Park JM; Lee SH; Roh SY; Kim IH
BMC Cancer; 2019 Dec; 19(1):1232. PubMed ID: 31852475
[TBL] [Abstract][Full Text] [Related]
25. The role of oxaliplatin in the adjuvant setting of different Lauren's type of gastric adenocarcinoma after D2 gastrectomy: a real-world study.
Cheng X; Yu S; Wang Y; Cui Y; Li W; Yu Y; Tang C; Jiang H; Ji Y; Sun Y; Wang X; Shen Z; Liu F; Liu TS
Gastric Cancer; 2019 May; 22(3):587-597. PubMed ID: 30426294
[TBL] [Abstract][Full Text] [Related]
26. Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial.
Yoshikawa T; Muro K; Shitara K; Oh DY; Kang YK; Chung HC; Kudo T; Chin K; Kadowaki S; Hamamoto Y; Hironaka S; Yoshida K; Yen CJ; Omuro Y; Bai LY; Maeda K; Ozeki A; Yoshikawa R; Kitagawa Y
JAMA Netw Open; 2019 Aug; 2(8):e198243. PubMed ID: 31373648
[TBL] [Abstract][Full Text] [Related]
27. Peripheral Venous Blood Platelet-to-Lymphocyte Ratio (PLR) for Predicting the Survival of Patients With Gastric Cancer Treated With SOX or XELOX Regimen Neoadjuvant Chemotherapy.
Chen L; Hao Y; Cong X; Zou M; Li S; Zhu L; Song H; Xue Y
Technol Cancer Res Treat; 2019 Jan; 18():1533033819829485. PubMed ID: 30760114
[TBL] [Abstract][Full Text] [Related]
28. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Bang YJ; Kim YW; Yang HK; Chung HC; Park YK; Lee KH; Lee KW; Kim YH; Noh SI; Cho JY; Mok YJ; Kim YH; Ji J; Yeh TS; Button P; Sirzén F; Noh SH;
Lancet; 2012 Jan; 379(9813):315-21. PubMed ID: 22226517
[TBL] [Abstract][Full Text] [Related]
29. Correlation of ERCC1 expression in peripheral blood lymphocytes with outcomes of patients with gastric cancer treated with oxaliplatin-based adjuvant chemotherapy.
Zhang YY; Gu KS; Wu HY; Yang F; Bu LJ; Zhao CC; Zhang YR
Genet Mol Res; 2015 Dec; 14(4):15921-9. PubMed ID: 26662383
[TBL] [Abstract][Full Text] [Related]
30. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Al-Batran SE; Homann N; Pauligk C; Goetze TO; Meiler J; Kasper S; Kopp HG; Mayer F; Haag GM; Luley K; Lindig U; Schmiegel W; Pohl M; Stoehlmacher J; Folprecht G; Probst S; Prasnikar N; Fischbach W; Mahlberg R; Trojan J; Koenigsmann M; Martens UM; Thuss-Patience P; Egger M; Block A; Heinemann V; Illerhaus G; Moehler M; Schenk M; Kullmann F; Behringer DM; Heike M; Pink D; Teschendorf C; Löhr C; Bernhard H; Schuch G; Rethwisch V; von Weikersthal LF; Hartmann JT; Kneba M; Daum S; Schulmann K; Weniger J; Belle S; Gaiser T; Oduncu FS; Güntner M; Hozaeel W; Reichart A; Jäger E; Kraus T; Mönig S; Bechstein WO; Schuler M; Schmalenberg H; Hofheinz RD;
Lancet; 2019 May; 393(10184):1948-1957. PubMed ID: 30982686
[TBL] [Abstract][Full Text] [Related]
31. Adoptive immunotherapy of human pancreatic cancer with lymphokine-activated killer cells and interleukin-2 in a nude mouse model.
Marincola FM; Da Pozzo LF; Drucker BJ; Holder WD
Surgery; 1990 Nov; 108(5):919-29. PubMed ID: 2237773
[TBL] [Abstract][Full Text] [Related]
32. Influence of the number and interval of treatment cycles on cytokine-induced killer cells and their adjuvant therapeutic effects in advanced non-small-cell lung cancer (NSCLC).
Gu Y; Lv H; Zhao J; Li Q; Mu G; Li J; Wuyang J; Lou G; Wang R; Zhang Y; Huang X
Int Immunopharmacol; 2017 Sep; 50():263-269. PubMed ID: 28711032
[TBL] [Abstract][Full Text] [Related]
33. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
Petrelli F; Labianca R; Zaniboni A; Lonardi S; Galli F; Rulli E; Rosati G; Corallo S; Ronzoni M; Cardellino GG; Mattioli R; Mambrini A; Ciuffreda L; Banzi M; Pusceddu V; Maiello E; Zampino M; Zagonel V; Marchetti P; Corsi D; Rimassa L; Cinieri S; Sobrero A
JAMA Oncol; 2020 Apr; 6(4):547-551. PubMed ID: 32053133
[TBL] [Abstract][Full Text] [Related]
34. The efficacy and safety of neoadjuvant chemotherapy on patients with advanced gastric cancer: A multicenter randomized clinical trial.
Zhao Q; Lian C; Huo Z; Li M; Liu Y; Fan L; Tan B; Zhao X; Zhang Z; Wang D; Liu Y; Guo H; Yang P; Tian Y; Li Y
Cancer Med; 2020 Aug; 9(16):5731-5745. PubMed ID: 32583567
[TBL] [Abstract][Full Text] [Related]
35. [Safety and short-term efficacy of apatinib combined with oxaliplatin and S-1 in the conversion treatment for gastric cancer with peritoneal metastasis].
Ye ZS; Zeng Y; Wei SH; Wang Y; Chen S; Lin ZT; Wang ZW; Chen XL; Chen LC
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):240-247. PubMed ID: 34645168
[No Abstract] [Full Text] [Related]
36. A clinical prognostic scoring system for resectable gastric cancer to predict survival and benefit from paclitaxel- or oxaliplatin-based adjuvant chemotherapy.
Qian J; Qian Y; Wang J; Gu B; Pei D; He S; Zhu F; Røe OD; Xu J; Liu L; Gu Y; Guo R; Yin Y; Shu Y; Chen X
Drug Des Devel Ther; 2016; 10():241-58. PubMed ID: 26966350
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of Adoptive Immune-cell Therapy in Patients with Advanced Gastric Cancer: A Retrospective Study.
Takimoto R; Kamigaki T; Okada S; Matsuda E; Ibe H; Oguma E; Naitoh K; Makita K; Goto S
Anticancer Res; 2017 Jul; 37(7):3947-3954. PubMed ID: 28668899
[TBL] [Abstract][Full Text] [Related]
38. Prognostic analysis of stage III gastric cancer after curative surgery according to the newest TNM classification.
Wei J; Yao T; Wang Y; Li L; Pan C; Zhang N
Clin Transl Oncol; 2019 Feb; 21(2):232-238. PubMed ID: 29968135
[TBL] [Abstract][Full Text] [Related]
39. Adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in Japanese patients with gastric cancer: a phase II study.
Fuse N; Bando H; Chin K; Ito S; Yoshikawa T; Tsuburaya A; Terashima M; Kawashima Y; Fukunaga T; Gotoh M; Emi Y; Yoshida K; Oki E; Takahashi S; Kuriki H; Sato K; Sasako M
Gastric Cancer; 2017 Mar; 20(2):332-340. PubMed ID: 26956689
[TBL] [Abstract][Full Text] [Related]
40. The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-II trial.
Wang X; Li S; Sun Y; Li K; Shen X; Xue Y; Liang P; Li G; Chen L; Zhao Q; Li G; Fu W; Liang H; Xin H; Suo J; Fang X; Zheng Z; Xu Z; Chen H; Zhou Y; He Y; Huang H; Zhu L; Yang K; Ji J; Ye Y; Zhang Z; Li F; Wang X; Tian Y; Park S; Chen L
BMC Cancer; 2021 Jan; 21(1):20. PubMed ID: 33402102
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]